FDA urges NGS for genome‑editing safety
The FDA issued draft best‑practice guidance for genome‑editing that emphasizes use of next‑generation sequencing as a core tool to mitigate safety risks. The guidance outlines NGS-centered approaches for assessing off‑target events and experiment metadata to support safety arguments. (Clinical Trials Arena)
Genome editing rewrites DNA, and the Food and Drug Administration now wants drugmakers to use next-generation sequencing as a standard safety check before those therapies reach patients. (fda.gov) The agency issued the draft guidance on April 14, 2026, through its Center for Biologics Evaluation and Research, and posted it for public comment through July 14, 2026. (fda.gov) Next-generation sequencing is a high-volume DNA reading tool, and the draft tells sponsors to use it in nonclinical studies to look for edits at the intended target and at unintended sites elsewhere in the genome. (fda.gov) The document also tells companies to use sequencing and bioinformatics, or software that sorts through DNA data, to check for “loss of genome integrity,” including larger structural damage such as rearrangements around edited DNA. (fda.gov) The guidance applies to both ex vivo therapies, where cells are edited outside the body and then returned to a patient, and in vivo therapies, where the edit happens directly inside tissue. (fda.gov) Food and Drug Administration reviewers said the new draft builds on a broader January 2024 genome-editing guidance and narrows in on one problem that has dogged the field: proving that a molecular cut happened only where developers intended. (fda.gov, fda.gov) That question has moved from theory to regulation as genome-editing medicines reach the market. In December 2023, the Food and Drug Administration approved Casgevy, a CRISPR-based treatment for sickle cell disease, and required postmarketing studies on off-target editing risk and long-term safety. (fda.gov) In the new draft, the agency says sponsors should spell out sequencing strategies, sample selection, analysis parameters, and reporting, so reviewers can judge whether a safety package is complete and reproducible. (fda.gov) The Federal Register notice says the recommendations are nonbinding and that companies may use another approach if it meets statutory and regulatory requirements for investigational new drug applications and biologics license applications. (govinfo.gov) For developers, the message is procedural as much as technical: if a therapy edits DNA, the Food and Drug Administration now wants a much clearer record of where the edit landed, what else changed, and how the company knows. (fda.gov)
